Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo

Oncotarget

Volumn 5, Issue 21, 2014, Pages 10342-10355

  Tang, Shou Hung ^a   Huang, Hsu Shan ^b   Wu, Hong Ui ^c   Tsai, Yi Ta ^d   Chuang, Mei Jen ^a   Yu, Cheng Ping ^a   Huang, Shih Ming ^e   Sun, Guang Huan ^a   Chang, Sun Yran ^f   Hsiao, Pei Wen ^g   Yu, Dah Shyong ^a   Cha, Tai Lung ^a,c,d,e,h  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Graduate Institute of Life Sciences at TKU   (Taiwan)

^d Department of Pediatrics   (Taiwan)

^e Department of Biochemistry ^*  (Taiwan)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^h NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Ezh2; G2 M cell cycle arrest; Nsc745885; Proteasome degradation

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; EMODIN; NSC 745885; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEASOME;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CANCER STAGING; CARCINOMA; CELL GROWTH; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOADJUVANT THERAPY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE; EMODIN; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PROTEASOME ENDOPEPTIDASE COMPLEX; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84916885240     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1867     Document Type: Article

References (56)

1. Rothenberg ML, Carbone DP and Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nature reviews Cancer. 2003; 3(4):303-309.
2. Blagosklonny MV. Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle. 2004; 3(8):1035-1042.
3. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011; 2(12):1352-1367.
4. Li JW and Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science. 2009; 325(5937):161-165.
5. Weissman KJ and Leadlay PF. Combinatorial biosynthesis of reduced polyketides. Nature reviews Microbiology. 2005; 3(12):925-936.
6. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P and Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes & development. 2002; 16(22):2893-2905.
7. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298(5595):1039-1043.
8. Czermin B, MelfiR, McCabe D, Seitz V, Imhof A and Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell. 2002; 111(2):185-196.
9. Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE and Simon JA. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111(2):197-208.
10. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA and Jaenisch R. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441(7091):349-353.
11. Pasini D, Bracken AP, Hansen JB, Capillo M and Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Molecular and cellular biology. 2007; 27(10):3769-3779.
12. Chamberlain SJ, Yee D and Magnuson T. Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem cells. 2008; 26(6):1496-1505.
13. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO and Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int. 2005; 75(3):252-257.
14. Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J and Cheng J. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013; 4(12):2532-2549.
15. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Jhnson TM, Giordano TJ, Palanisamy N and Chinnaiyan AM. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012; 3(9):1011-1025.
16. Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, Noske DP, Tannous BA and Wurdinger T. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 2010; 1(8):710-720.
17. Shen H, Morrison CD, Zhang J, Underwood W, 3rd, Yang N, Frangou C, Eng K, Head K, Bollag RJ, Kavuri SK, Rojiani AM, Li Y, Yan L, Hill A, Woloszynska-Read A, Wang J, et al. 6p22.3 amplification as a biomarker and potential therapeutic target of advanced stage bladder cancer. Oncotarget. 2013; 4(11):2124-2134.
18. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419(6907):624-629.
19. Karanikolas BD, Figueiredo ML and Wu L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Molecular cancer research: MCR. 2009; 7(9):1456-1465.
20. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S and De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011; 2(9):669-683.
21. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(20):11606-11611.
22. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD and Kleer CG. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. The American journal of pathology. 2009; 175(3):1246-1254.
23. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP and Hung MC. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005; 310(5746):306-310.
24. Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA and Huang H. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nature cell biology. 2010; 12(11):1108-1114.
25. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, Yang CC, Yang JY, Lin CY, Lai CC and Hung MC. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 2011; 13(1):87-94.
26. Wang HH and Chung JG. Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Current microbiology. 1997; 35(5):262-266.
27. Chang CH, Lin CC, Yang JJ, Namba T and Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. The American journal of Chinese medicine. 1996; 24(2):139-142.
28. Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML and Chu SH. Immunosuppressive effect of emodin, a free radical generator. European journal of pharmacology. 1992; 211(3):359-364.
29. Jing X, Ueki N, Cheng J, Imanishi H and Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Japanese journal of cancer research: Gann. 2002; 93(8):874-882.
30. Cha TL, Qiu L, Chen CT, Wen Y and Hung MC. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer research. 2005; 65(6):2287-2295.
31. Cha TL, Chuang MJ, Tang SH, Wu ST, Sun KH, Chen TT, Sun GH, Chang SY, Yu CP, Ho JY, Liu SY, Huang SM and Yu DS. Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth. Mol Carcinog. 2013.
32. Chase A and Cross NC. Aberrations of EZH2 in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(9):2613-2618.
33. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. The EMBO journal. 2003; 22(20):5323-5335.
34. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature genetics. 2007; 39(2):237-242.
35. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, ReubinoffBE, Bergman Y, Simon I and Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature genetics. 2007; 39(2):232-236.
36. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I and Laird PW. Epigenetic stem cell signature in cancer. Nature genetics. 2007; 39(2):157-158.
37. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y and Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006; 439(7078):871-874.
38. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA and Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Molecular and cellular biology. 2001; 21(13):4330-4336.
39. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, Yuan GC and Orkin SH. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Molecular cell. 2008; 32(4):491-502.
40. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(17):2846-2853.
41. Sparmann A and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature reviews Cancer. 2006; 6(11):846-856.
42. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005; 122(6):835-847.
43. Ougolkov AV, Bilim VN and Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(21):6790-6796.
44. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, Sun L, Zhang Y, Chen Y, Li R, Zhang Y, Hong M and Shang Y. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Molecular and cellular biology. 2007; 27(14):5105-5119.
45. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004; 23(34):5759-5769.
46. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L and Wang Z. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer biology & therapy. 2010; 10(8):788-795.
47. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB and Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Molecular cancer therapeutics. 2011; 10(2):325-335.
48. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET and Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & development. 2007; 21(9):1050-1063.
49. Balasubramanian S, Chew YC and Eckert RL. Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells. Molecular pharmacology. 2011; 80(5):870-878.
50. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
51. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012; 338(6113):1465-1469.
52. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA and Jansen JH. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature genetics. 2010; 42(8):665-667.
53. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature medicine. 2012; 18(2):298-301.
54. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, Radlwimmer B, Hojfeldt JW, Truffaux N, Castel D, Schubert S, Ryzhova M, et al. Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer cell. 2013; 24(5):660-672.
55. Hua MY, Yang HW, Liu HL, Tsai RY, Pang ST, Chuang KL, Chang YS, Hwang TL, Chang YH, Chuang HC and Chuang CK. Superhigh-magnetization nanocarrier as a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials. 2011; 32(34):8999-9010.
56. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, Fan PL and Hsiao PW. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(3):840-850.